S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory  Primary Amyloidosis Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials